Hi Swift SX
In the near-term I would expect news on the following within the next 3-months ish (June-August):
1. Reagent Development (based on 14 May 2018 cloning is underway at which point this becomes nearly fully derisked and goes into pre-production steps of characterisation, small scale manufacturing and biobanking of the "blue-print"). To date this is trending ahead of the timelines indicated in the GANTT chart appearing in the prospectus and announcements.
2. IVD Kit Development and Production Transfer
3. Commencement of Study 6: Validation Study (comparison of clinical performance of old and new reagents before and making any adjustments before going into study 7).
4. Enrolment of study 7 Clinical Trial Sites and Potential for Early Patient Recruitment (I would expect given the previous interest by BUPA & the fact that colorectal cancer is the third largest cause of cancer related mortality that there may be some government support to accelerate commercialisation). (Source http://sprout8.com/rhy-research-report/)
The other obvious catalyst is general rerate following tightening of the capital structure, which we have seen - top 50 now exceed 70% and we've seen a highly successful small cap fund enter with 2.2% of the company (here's hoping they go substantial).
Bear in mind, out of the 100.75M shares on issue, 47.5M shares are escrowed..
And importantly, the valuation already trails less well progressed peers by a factor of 5x and statistically and cost inferior, Colvera (US$300 per test) by 10x (c. $200M valuation),.
Fundamentally the story remains one of the best I have found on the ASX in the best performing sector of 2018, globally (Health Care). However as we can all probably appreciate, where there are unrealistic expectations set and shares go into the wrong hands in the IPO, which is what RHY went through, there will be stag selling and overhang when those unrealistic expectations are not met.
Lots of blue sky from here IMO and I have used this as an opportunity to get my average to c. 0.18.
Cheers
5x8's
New Feature Announcement!
We’re excited to introduce the DealRoom portal, now live on site, providing users with exciting access to private equity opportunities for both pre-IPO and publicly listed companies.
See full details by selecting the new menu item named 'DealRoom' on our main menu bar or click below.
Stay ahead of the market, with HotCopper.